New HIV injection shows promise in early safety trial
NCT ID NCT05349968
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested multiple doses of an injectable drug called lipovirtide in 24 adults with HIV who had never taken antiretroviral therapy. The main goal was to check safety and how the drug moves through the body, with a secondary look at whether it can lower HIV levels. The study is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lipovirtide
What this could lead to
If this works, it could point toward a new injectable treatment option for HIV that helps control the virus without daily pills.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so results may not apply broadly. The drug may prove unsafe or ineffective in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing You'an Hospital, Beijing Medical University
Beijing, China